The global sales of whole plasmid sequencing are estimated to be worth USD 636.2 million in 2025 and are anticipated to reach a value of USD 1,548.2 million by 2035. Sales are projected to rise at a CAGR of 9.3% over the forecast period between 2025 and 2035. The revenue generated by whole plasmid sequencing in 2024 was USD 582.1 million.
The whole plasmid sequencing (WPS) industry is growing remarkably because of its increasing importance in genomics research and biotechnology applications. WPS utilizes advanced sequencing technologies, such as nanopore sequencing, that enable analysis of the full plasmid DNA in single run.
This long-read sequencing technique offers the big plus than traditional methods, which usually provide information only on small fragments and cannot give the full overview of the plasmid structure. WPS is an instrument that becomes increasingly indispensable in research when complete insight into plasmid design, modification, and integrity is necessary.
It enables the structural variations, mutations, and possible cloning errors that make the real picture of plasmid content more accurate for successful genetic manipulation.
Global Whole Plasmid Sequencing Industry Assessment
| Attributes | Key Insights |
|---|---|
| Estimated Size, 2025 | USD 636.2 million |
| Projected Size, 2035 | USD 1,548.2 million |
| Value-based CAGR (2025 to 2035) | 9.3% |
The market growth is also due to growing personalized medicine, gene therapies, and advanced drug discovery applications that require such systems. WPS finds its vital application in such disciplines, which are related to proper knowledge about the genetic composition of plasmids that are applied in drug discovery and gene therapy.
Particularly in the pharma sector, the technology holds a pivotal position in creating new drugs based on plasmids through maintaining precision and stability. Furthermore, the growing emphasis on AMR research has spurred the application of WPS in pathogen typing and resistance gene detection.
WPS facilitates rapid and high-throughput plasmid sequencing, which may allow for the identification of bacterial pathogens and resistance features much more rapidly than conventional techniques and may lead to a substantial improvement in patient treatment outcomes, particularly in infectious disease diagnosis.
Besides that, WPS contributes in synthetic biology by allowing genetically modified organisms and novel biological systems. As the technology becomes more accessible, it will drive innovation in agriculture, environmental science, and several industrial applications.
The rapid and accurate sequencing of plasmids further facilitates translational research, disease modeling, and molecular diagnostics. Overall, the whole plasmid sequencing market is at an edge that promises to grow further with increasing application usage in research, healthcare, and biotechnology.
Explore FMI!
Book a free demo
Development of Nanopore Sequencing is Boosting the Industry for Whole Plasmid Sequencing
The development of nanopore sequencing technology is one of the major factors driving growth in the whole plasmid sequencing market. Nanopore sequencing is a third-generation sequencing technology that provides long, continuous reads highly useful for large plasmids and the assembly of complex plasmid structures.
Unlike other methods of sequencing, nanopore sequencing does not require primer design, preparation, or troubleshooting. Instead, plasmids are simply cut and adapters attached, so the sequencing process can move ahead without difficulties.
This capability for complete plasmid sequencing in one run, not limited by fragmentation, represents a huge saving in time. There is also no need to directly sequence the entire plasmid without relying on the assembly of fragmented sequences.
It allows more complex analyses that make structural variations, mutations, and other genetic alterations in plasmids easier to detect, an important requirement for gene therapy development or synthetic biology applications.
Nanopore sequencing has the impact overall plasmid sequencing market. The removal of primer-related problems that are one of the most common causes of errors in other sequencing has contributed to faster research and development. In fact, in a study report, a researcher saved an entire week's work that would have been used in troubleshooting primer designs.
Being able to accelerate sequencing by this factor has implications in the real world; faster sequencing allows for quicker insights into genetic modification, pathogen identification, and the development of new treatments. Development in nanopore sequencing has not only eased the sequencing process but also opened the doors for rapid, high-throughput applications in research and clinical diagnostics.
Data Filtering and Error Correction Techniques are enhancing the Accuracy of Whole Plasmid Sequencing
Data processing in sequencing technologies is a very important aspect for the assurance of high-quality, correct results. Development in sequencing technologies has placed a big trend in the whole plasmid sequencing market; advanced tools for data filtering and error correction. Data filtering involves the cleaning of low-quality sequences and removal of contaminants that would result in compromised data output and error correction.
Software tools such as Medaka, used in nanopore sequencing for error correction in the reads of sequencing, is gaining traction, especially with long-read technologies. These tools have been quite instrumental in refining such data that the output of sequencing is as accurate as it gets, reducing time-wasting manual interventions.
Whole plasmid sequencing will be greatly dependent on error-correction methods that can surmount some of the inherent challenges of complex plasmid structures and mutations that lower-quality sequencing methods may not easily detect.
This trend is important within the context of whole-plasmid sequencing, whereby accuracy directly impacts downstream applications, ranging from gene therapy development to pathogen identification. Similarly, with continuous improvement in data processing techniques and enhancement of automation in data analysis, whole-plasmid sequencing becomes a valid and useful tool in research for more accurate details about genetic modifications and genomic structure.
Rapid Turnaround Times in Sequencing Techniques is Creating Opportunities for Whole Plasmid Sequencing Market Growth
Rapid turnaround times for sequencing technologies create a great opportunity for the growth of the whole plasmid sequencing market. Growing demand for faster and more accurate results will ensure that the rapid sequencing of plasmids, highly critical in a range of applications such as pathogen identification, drug development, and personalized medicine, takes place accordingly.
Currently promising results in hours compared to days and even weeks with rapid advances in the areas of Next Generation Sequencing and Nanopore technologies, it may change healthcare and diagnostics in the future.
Faster sequencing allows for more clinical and research workflow efficiency, so researchers can execute more experiments and accelerate their outcomes. In the clinical diagnostic scenario, speed in identifying a pathogen in time, antimicrobial resistance detection, and therefore therapeutic decision-making are required.
Shorter turnaround time in sequencing can accelerate the process of new therapeutics and vaccine development down drug development pipelines, a feature important to disease combat such as cancer and infectious disease.
Also, the reduced turnaround times with the next generation sequencing platforms lower the total operation expense, which would further democratize such sophisticated technologies to smaller-sized research labs and hospitals.
As more affordable sequencing platforms emerge, the entire plasmid sequencing market will be subject to increased adoption, enabling further growth in genomics research and clinical diagnostics. Faster and more accurate sequencing is a great opportunity for those industries that rely on genomic data.
Sanger Sequencing Limitations are restraining the Full Potential of Plasmid Sequencing
Sanger sequencing, in the context of whole plasmid sequencing, has a limitation in that it does not allow for the proper analysis of large and complex structures of plasmids. It involves the sequencing of small DNA fragments that are then assembled into longer sequences.
In the case of plasmid sequencing, the Sanger sequencing technique does not serve well because, in general, it focuses on the insert region while the rest of the plasmid structure remains unconsidered. This makes it unsuitable for the complete characterization of plasmids, which more often than not require deep understanding even for the whole sequence, including regulatory elements and possible mutations across the plasmid.
Moreover, primer design and debugging for Sanger sequencing further complicate this process, introducing delays and possible mistakes, especially when working with larger plasmids. Many researchers struggle to sequence large plasmids or those with complex structure features.
While Sanger sequencing will work for small-scale applications and highly targeted areas, it is less effective for comprehensive plasmid analysis. Inability to provide precise and efficient analysis of the full plasmid sequence limits the role that Sanger sequencing which hinders the overall market.
The global whole plasmid sequencing industry recorded a CAGR of 6.8% during the historical period between 2020 and 2024. The growth of whole plasmid sequencing industry was positive as it reached a value of USD 1,548.2 million in 2035 from USD 636.2 million in 2025.
The whole plasmid sequencing market has changed remarkably over the years, with advancements in the sequencing technologies being at the center of the market growth. Generally, plasmid sequencing has relied heavily on traditional methods such as Sanger sequencing.
This, although very useful, did lack throughput and the ability to sequence large and complex plasmids. These early approaches had their focus on small DNA fragment sequencing, which then required the assembly of many short reads into a complete plasmid sequence.
While this approach was sufficient for small projects, it became increasingly unsuitable, as higher accuracy and speed were needed, especially in clinical and research contexts.
Until the establishment of the NGS technologies, enabling the sequencing of bigger size and more complex plasmids in a more accurate and proficient way. NGS provided the means for cost-efficient analyses compared to conventional approaches, with shorter times compared to conventional ones, or at least greatly improved scalability for research projects.
Improved sequencing technologies gave rise to some long-read sequencing methods, such as the Nanopore technique, which allows for the complete sequencing of entire plasmids in one run, while avoiding prior primer design or other troubleshooting steps. Thus, great steps are taken toward further accomplishment of genomics research, gene therapy, and diagnostic applications.
The future of whole-plasmid sequencing is brighter still, with enormous technological and applications-based progress on the horizon. Besides improvements in accuracy, rapidity, and cost, future enhancement of the sequencing platforms will be very much on the way.
The introduction of machine learning and artificial intelligence into the sequencing protocols is expected to further ameliorate data for analysis, thereby giving researchers an even clearer resolution with which to accelerate drug development, personalized medicine, and many other biotechnology applications.
With more affordable sequencing as technology advances, whole plasmid sequencing will become an inexpensive option for small research laboratories, clinical sites, and biopharmaceutical companies such that these powerful tools may be applied to a larger spectrum of applications.
This is only the start of what plasmid sequencing has to offer a variety of industries, and surely the future will be rosy as far as genomic studies and medical progress are concerned.
Illumina, Inc., Thermo Fisher Scientific, Pacific Biosciences (PacBio), and Oxford Nanopore Technologies are known to be the tier 1 firms in the entire whole plasmid sequencing industry with the possession of 64.7%. These market leaders have gained prominence by introducing cutting-edge innovations, extensive product ranges, and rich knowledge in the field of sequencing technologies.
Their sophisticated platforms and solutions have achieved high standards in accuracy, velocity, and trustworthiness for whole plasmid sequencing and are the best choice for global researchers and institutions.
BGI Genomics, Roche Sequencing, Qiagen, Agilent Technologies, and PerkinElmer holding 26.2% market share and being tier 2 companies in the entire plasmid sequencing industry. Although these companies are not at the top of their game, they have a great contribution by offering unique and versatile solutions that target specific market demands.
Their emphasis on providing low-cost sequencing reagents and services has enabled them to become trustworthy partners for smaller research institutions, academias, and special niche markets in biotechnology and genomics.
The section below covers the industry analysis for the whole plasmid sequencing market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East & Africa, is provided.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| USA | 3.9% |
| Canada | 6.8% |
| Germany | 3.8% |
| France | 6.3% |
| Italy | 5.7% |
| UK | 4.5% |
Germany’s whole plasmid sequencing industry outlook projects a CAGR of 3.8% between 2025 and 2035. The Germany holds highest market share in European market.
Germany's progressive steps toward integrating genomic medicine into its healthcare system are fostering growth in the whole plasmid sequencing market. Through initiatives like the SGB V §64e pilot program under the genomDE strategy, the country is transitioning from gene panel-based sequencing to comprehensive whole genome sequencing (WGS).
This shift is designed to enhance patient outcomes in oncology and rare disease treatments, laying the groundwork for advancements in genetic research and therapeutic development.
Whole plasmid sequencing has a complementary role in this shift, being an essential tool for the validation and optimization of therapeutic vectors and the investigation of genetic mechanisms. The demand for precise plasmid analysis increases as Germany accepts genomic techniques requiring scalable, high-fidelity sequencing technologies.
Also, the focus on personalized medicine has expanded the demand for plasmid-based research for gene therapy and targeted therapy development.
Germany's organized programs also promote public-private collaborations between healthcare providers, academic centers, and sequencing technology companies. The partnerships are revolutionizing sequencing platforms, and the efficiency and availability of plasmid sequencing is increasing.
With a focus on genomic medicine, Germany is not only leading in healthcare but laying the foundation for a booming industry in whole plasmid sequencing, supported by its emphasis on innovation and precision in medical science.
United States market is anticipated to grow at a CAGR of 3.9% throughout the forecast period.
The application of advanced sequencing technologies has shaped the United States' decision to develop superior public health surveillance systems. This, in turn, is driving the entire plasmid sequencing market. Various public health agencies have taken initiatives by normally utilizing next-generation sequencing and WGS to track microbial foodborne pathogens.
With nanopore-based platforms like the MinION, the United States has been able to offer rapid and inexpensive microbial genome sequencing, including plasmids related to virulence and AMR. This practice supports outbreak response capability, enabling the quick detection and removal of contaminated food items, thus significantly lowering the occurrence of illness and death.
Technological advancements in sequencing workflows have also resolved previous problems, including raw read high error rates, thereby making long-read technologies more robust.
Such breakthroughs have established plasmid sequencing as a critical instrument in pathogen characterization and public health planning, strengthening the USA position as a global front-runner in the uptake and evolution of genomic technologies for health and safety.
Advancing Therapeutic Development Positions United Kingdom as a Leader in Whole Plasmid Sequencing Market
United Kingdom is expected to hold dominating position in East Asia market of whole plasmid sequencing and is anticipated to grow at a CAGR of 4.5% throughout the forecast period.
The United Kingdom has been emerging as one of the knowledge hubs for biopharmaceutical innovation, and continuous therapeutic development brings about an increased need for WPS. This technique makes tDNAs highly important for gene therapies, vaccine development, and synthetic biology.
Excellent research infrastructure in the UK gives support to the newest application areas. Precision medicine and initiatives, along with recent interest in the development of therapies based on genes, accelerated the adoption of WPS.
Healthcare and academic organizations are thus incorporating WPS to ensure the integrity of plasmid vectors used in clinical trials and biopharmaceuticals. The UK’s emphasis on stringent quality control and regulatory compliance aligns with the need for accurate plasmid sequencing to eliminate risks associated with mutations or structural instabilities.
This focus enhances the reliability of therapeutic interventions, reinforcing the UK’s leadership in biotechnology and pharmaceutical research.
The section contains information about the leading segments in the industry. The whole plasmid industry outlook indicates that, based on sequencing technology, sequencing by synthesis is expected to account for 38.5% of the global market share in 2025.
| Sequencing Technique | Value Share (2025) |
|---|---|
| Sequencing by Synthesis | 38.5% |
Sequencing by Synthesis (SBS) with its incomparable accuracy, scalability, and established lead in the genomics market, is one of the leading options in the WPS market. Sequencing by Synthesis is gaining rapid momentum in the whole plasmid sequencing market due to its unrivaled accuracy and versatility.
This widely adopted technology of NGS, resultantly, offers very high precisions, incorporating one base at a time labeled nucleotides; hence, it is recommended for detecting genetic variations and mutations in plasmids. In application, such as therapeutic validation of plasmids and studies concerned with microbial resistance, SBS yields a very critical quality read.
The scalability of SBS platforms combined with growing demands for large-scale genomic research and manufacturing of biopharmaceuticals, supports SBS. Advanced software tools that simplify data analysis and provide reliable genome assembly further support SBS as an efficient solution in plasmid sequencing.
While long-read technologies like Nanopore and SMRT do provide some advantages, SBS remains one of the finest technologies a researcher can ask for when in need of reliable and accurate sequencing methodologies.
| Product Type | Value Share (2025) |
|---|---|
| Consumables | 71.2% |
Consumables are very significant in whole plasmid sequencing processes and thus contribute remarkably towards the market growth of WPS. Products such as sequencing reagents, primers, chips, and buffers are important in ensuring the quality and time-effectiveness of the sequencing process.
Where high-quality sequencing technologies experience an increase in demand, consumables that supplement such technologies also increase in demand.
In this respect, the increasing demand for next-generation sequencing processes such as SBS and Nanopore sequencing raises the interest in a huge supply of high-end consumables to keep results constant and error-free. This is because, with increasing dependency on consumables, companies focus on improving their offerings for better performance and lower costs.
Additionally, affordable and efficient consumables are required to keep up with the growing WPS market to further maintain overall scalability and efficiency of sequencing operations. The continuing evolution of consumables is contributing toward meeting the demands for an expanding whole plasmid sequencing market by assuring seamless product integration both for researchers and for clinicians.
The entire plasmid sequencing industry is very dynamic, and various collaborations and approvals are occurring to increase its growth. Major companies in the market are actively working with the regulatory bodies to make their products comply with the required standards.
Companies dealing in this industry are attempting to strengthen their positions in the market through strategic partnerships with academic institutions as well as biopharmaceutical companies. They contribute to the rapid advancement of innovative sequencing solutions, broadening application scope, and keeping the firm competitive in the market:
Recent Industry Developments in Whole Plasmid Sequencing Market
The global whole plasmid sequencing industry is projected to witness CAGR of 9.3% between 2025 and 2035.
The global whole plasmid sequencing industry stood at USD 582.1 million in 2024.
The global whole plasmid sequencing industry is anticipated to reach USD 1,548.2 million by 2035 end.
France is expected to show a CAGR of 6.3% in the assessment period.
The key players operating in the global whole plasmid sequencing industry include Illumina, Inc., Thermo Fisher Scientific, Pacific Biosciences (PacBio), Oxford Nanopore Technologies, BGI Genomics, Roche Sequencing, Qiagen, Agilent Technologies, PerkinElmer, Genewiz (a Brooks Automation company) and Others
Specialty Medical Chairs Market Trends - Size, Growth & Forecast 2025 to 2035
Surgical Drapes Market Overview - Growth, Demand & Forecast 2025 to 2035
Super Resolution Microscope Market Insights - Size, Share & Forecast 2025 to 2035
Portal Hypertension Management Market Trends - Size, Growth & Forecast 2025 to 2035
Precocious Puberty Treatment Market Overview – Growth, Trends & Demand Forecast 2025 to 2035
Pleural Diseases Therapeutics Market – Drug Trends & Future Outlook 2025 to 2035
Whole Plasmid Sequencing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
